

REMARKS

Applicant has inserted priority information on the front page of the application as required by 37 U.S.C. §1.78. By the foregoing amendments, Applicant has also amended the application to place the specification and claims into proper format for U.S. practice, and to insert the abstract (which contains the same text as that appearing on the face page of the international application as published) into the appropriate location in the specification. Applicant has also added Sequence Identifiers at pages 29 and 30.

The left-hand column of Table 1 has been amended to correct formatting errors and to conform the left-hand column of the Table to the specification. The data for a 2xmet-2x cross are found in the specification at page 25, lines 10-14, and also provided in row 12 of Table 1. The data for a 2x-2xmet cross are found in the specification at page 25, lines 16-20, and also provided in row 10. Footnote 8 indicates that the data in rows 11 and 13 was obtained from a subsequent experiment. Thus, the cross shown in rows 10-11 is a 2x-2xmet cross, and the cross shown in rows 12-13 is a 2xmet-2x cross. The left-hand column of Table 1 has been amended at rows 11 and 13 to reflect the proper notation for the cross.

A 2xmet-2xmet cross was used for comparison purposes, as indicated at page 25, lines 14-16 and 17-20. The results of the cross shown in row 8 have the number of peripheral endosperm nuclei, chalazal endosperm volume and seed weight that match the percentage differences indicated at page 25. Thus, row 8 is the 2xmet-2xmet cross used for comparison. Footnote 8 indicates that the data in row 9 was obtained from a subsequent experiment. Therefore, the cross shown in rows 8-9 is a 2xmet-2xmet cross, and the left-hand column of Table 1 has been amended at rows 8-9 to reflect the proper notation. Footnote 8 of Table 1 has also been amended to correct typographical errors and for grammatical clarity.

Applicant respectfully requests entry of the amendments above prior to examination. No new matter is added by these amendments. The amendments to the sequence listing merely adds sequence identifier numbers.

Original claims 1-35 have been cancelled and new claims 36 – 73 are submitted. New independent claims 36 and 62 are directed to methods for the production of seeds. New

Applicant : Roderick J. Scott
Serial No. : Not Assigned
Filed : November 6, 2003
Page : 12 of 12

Attorney's Docket No.: 11696-067002

independent claim 50 is directed to a transgenic plant. Support for claims 36-73 can be found throughout the specification, e.g., at page 10, lines 27-30, page 14, lines 8-11, page 15, line 30 to page 16, line 2, page 16, lines 16-28, page 17, lines 1-7, page 18, line 26 to page 19, line 2, page 21, lines 23-26, page 25, line 9 to page 26, line 12, and page 31, lines 16-28.

In view of the above, Applicant respectfully requests favorable consideration of claims 36-73.

Enclosed is \$162.00 for excess claim fees. The enclosed filing fee takes into account the claims pending following entry of this Preliminary Amendment. Please apply any other charges or credits to Deposit Account 06-1050.

Respectfully submitted,

Date: Nov 6, 2003

Ronald C. Lundquist
Ronald C. Lundquist, Ph.D.
Reg. No. 37,875

Fish & Richardson P.C., P.A.
60 South Sixth Street
Suite 3300
Minneapolis, MN 55402
Telephone: (612) 335-5070
Facsimile: (612) 288-9696